Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Bioatla Inc
BCABCurrent price
2.09 USD
+0.14 USD (+7.18%)
Last closed
1.92 USD
Company
www.bioatla.com
ISIN
US09077B1044
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
96 188 040 USD
Yield for 12 month
+12.97 %
1Y
3Y
5Y
10Y
15Y
BCAB
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California. Address: 11085 Torreyana Road, San Diego, CA, United States, 92121
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
9.75 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
-103 731 000 USD
Last Year
-1 199 000 USD
Current Quarter
-229 000 USD
Last Quarter
-240 000 USD
Key Figures BCAB
1 year
3 years
5 years
10 years
EBITDA
-108 878 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-55.38 %
PEG Ratio
–
Return On Equity TTM
-134.14 %
Wall Street Target Price
9.75 USD
Revenue TTM
–
Book Value
0.65 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
31.6 %
Dividend Yield
–
Gross Profit TTM
-79 347 000 USD
Earnings per share
-2.17 USD
Diluted Eps TTM
-2.17 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics BCAB
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History BCAB
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation BCAB
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
134.3737
Price Sales TTM
989.2236
Enterprise Value EBITDA
0.3052
Price Book MRQ
3.0662
Financials BCAB
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators BCAB
For 52 weeks
1.14 USD
4.02 USD
50 Day MA
1.86 USD
Shares Short Prior Month
4 466 935
200 Day MA
2.15 USD
Short Ratio
2.96
Shares Short
5 242 717
Short Percent
12.13 %
BeatStart